Verapamil modulates NFAT2 to inhibit tumor growth and potentiates PD1ab immune checkpoint inhibitor therapy in cervical cancer treatment

References

• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.
   PubMed Web of Science ®Google Scholar
• Kućmierz J, Frąk W, Młynarska E, et al. Molecular interactions of arterial hypertension in its target organs. Int J Mol Sci. 2021;22(18):9669.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Yano Y, Itoh H, et al. Untreated hypertension and subsequent incidence of colorectal cancer: analysis of a nationwide epidemiological database. J Am Heart Assoc. 2021;10(22):e022479.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen L, Qian J, et al. Association between hypertension and oral cancer prognosis in non-smoking and non-drinking women. Wei Sheng Yan Jiu. 2021;50(6):944–951.
   PubMedGoogle Scholar
• Shi J, Chen G, Wang H, et al. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): a post hoc analysis of the ALTER0303 trial. Thorac Cancer. 2021;12(17):2345–2351. doi:10.1111/1759-7714.14076.
   PubMed Web of Science ®Google Scholar
• Seo J-H, Kim Y-D, Park C-S, et al. Hypertension is associated with oral, laryngeal, and esophageal cancer: a nationwide population-based study. Sci Rep. 2020;10(1):10291. doi:10.1038/s41598-020-67329-3.
   PubMed Web of Science ®Google Scholar
• Sionakidis A, McCallum L, Padmanabhan S. Unravelling the tangled web of hypertension and cancer. Clin Sci. 2021;135(13):1609–1625. doi:10.1042/CS20200307.
   Web of Science ®Google Scholar
• Zeng X, Zeng D, Cheng J, et al. Influence of hypertension on the survival of Non-Small cell lung cancer patients with type 2 diabetes mellitus. Med Sci Monit. 2020;26:e921676. doi:10.12659/MSM.921676.
   PubMed Web of Science ®Google Scholar
• Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21(Suppl 2):183s–189s.
   PubMedGoogle Scholar
• Hamann SR, Blouin RA, McAllister RG. Jr., Clinical pharmacokinetics of verapamil. Clin Pharmacokinet. 1984;9(1):26–41. doi:10.2165/00003088-198409010-00002.
   PubMed Web of Science ®Google Scholar
• Fan GF, Pan JJ, Fan PS, et al. The clinical observation of verapamil in combination with interventional chemotherapy in advanced gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22(17):5508–5518.
   PubMed Web of Science ®Google Scholar
• Nandi SK, Roychowdhury T, Chattopadhyay S, et al. Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of kaempferol in synergism with verapamil. Toxicol Appl Pharmacol. 2022;437:115887. doi:10.1016/j.taap.2022.115887.
   PubMed Web of Science ®Google Scholar
• Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348(9026):493–497. doi:10.1016/S0140-6736(96)04277-8.
   PubMed Web of Science ®Google Scholar
• Rotshild V, Azoulay L, Feldhamer I, et al. Calcium channel blockers and the risk for lung cancer: a population-based nested case-control study. Ann Pharmacother. 2019;53(5):445–452. doi:10.1177/1060028018814684.
   PubMed Web of Science ®Google Scholar
• Colt JS, Hofmann JN, Schwartz K, et al. Antihypertensive medication use and risk of renal cell carcinoma. Cancer Causes Control. 2017;28(4):289–297. doi:10.1007/s10552-017-0857-3.
   PubMed Web of Science ®Google Scholar
• Wan Q, Chu YX, Zheng A, et al. Effects of verapamil on the proliferation and migration of cervical cancer cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 2011;42(1):78–81.
   PubMedGoogle Scholar
• Saporiti A, Brocchieri A, Porta C, et al. Effect of different platelet agonists on intracellular free Ca++ concentrations in human tumor cells: possible role in tumor growth. Int J Cancer. 1995;62(3):291–296. doi:10.1002/ijc.2910620310.
   PubMed Web of Science ®Google Scholar
• Choudhuri SK. Deactivation of P-glycoprotein by a novel compound, oxalyl bis (N-phenyl) hydroxamic acid. Neoplasma. 2002;49(4):272–277.
   PubMed Web of Science ®Google Scholar
• Osmak M. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine. Neoplasma. 1993;40(2):97–101.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.00561.
   PubMed Web of Science ®Google Scholar
• Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119(2):317–327. doi:10.1002/ijc.21775.
   PubMed Web of Science ®Google Scholar
• Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
   PubMed Web of Science ®Google Scholar
• Ellis PM, Vella ET, Ung YC. Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(5):444–459.e1. doi:10.1016/j.cllc.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Wu L, Lin W, Liao Q, et al. Calcium channel blocker nifedipine suppresses colorectal cancer progression and immune escape by preventing NFAT2 nuclear translocation. Cell Rep. 2020;33(4):108327. doi:10.1016/j.celrep.2020.108327.
   PubMed Web of Science ®Google Scholar
• Al-Habsi M, Chamoto K, Matsumoto K, et al. Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice. Science. 2022;378(6618):eabj3510. doi:10.1126/science.abj3510.
   PubMed Web of Science ®Google Scholar
• Lee Y-R, Chen M, Lee JD, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364(6441):eaau0159. doi:10.1126/science.aau0159.
   Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z.
   PubMed Web of Science ®Google Scholar
• Midtbø K, Hals O, Lauve O, et al. Studies on verapamil in the treatment of essential hypertension: a review. Br J Clin Pharmacol. 1986;21(Suppl 2):165s–171s.
   PubMedGoogle Scholar
• McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989;38(1):19–76. doi:10.2165/00003495-198938010-00003.
   PubMed Web of Science ®Google Scholar
• Rotshild V, Azoulay L, Zarifeh M, et al. The risk for lung cancer incidence with calcium channel blockers: a systematic review and meta-analysis of observational studies. Drug Saf. 2018;41(6):555–564. doi:10.1007/s40264-018-0644-4.
   PubMed Web of Science ®Google Scholar
• Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1–9. doi:10.1016/j.critrevonc.2017.12.003.
   PubMed Web of Science ®Google Scholar
• Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, et al. The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain study. PLoS One. 2016;11(8):e0159672. doi:10.1371/journal.pone.0159672.
   PubMed Web of Science ®Google Scholar
• Cao L, Zhang S, Jia C-M, et al. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. BMC Urol. 2018;18(1):17. doi:10.1186/s12894-018-0318-7.
   PubMedGoogle Scholar
• Ni H, Rui Q, Zhu X, et al. Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8(37):62545–62560. doi:10.18632/oncotarget.19117.
   PubMedGoogle Scholar
• Zhao Y, Wang Q, Zhao X, et al. Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies. Clin Exp Hypertens. 2018;40(1):22–27. doi:10.1080/10641963.2017.1288736.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Soldera S, Yin H, et al. Use of calcium channel blockers and risk of breast cancer: a population-based cohort study. Epidemiology. 2016;27(4):594–601. doi:10.1097/EDE.0000000000000483.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65–82. doi:10.1016/S1470-2045(10)70260-6.
   PubMed Web of Science ®Google Scholar
• Holmes S, Griffith EJ, Musto G, et al. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol. 2013;37(6):881–885. doi:10.1016/j.canep.2013.09.001.
   PubMed Web of Science ®Google Scholar
• Veytia-Bucheli JI, Alvarado-Velázquez DA, Possani LD, et al. The Ca(2+) channel blocker verapamil inhibits the in vitro activation and function of T lymphocytes: a 2022 reappraisal. Pharmaceutics. 2022;14(7):1478. doi:10.3390/pharmaceutics14071478.
   PubMed Web of Science ®Google Scholar
• Dönmez Y, Akhmetova L, İşeri ÖD, et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol. 2011;67(4):823–828. doi:10.1007/s00280-010-1385-y.
   PubMed Web of Science ®Google Scholar
• Li P, Zhong D, Gong PY. Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells. Biochem Biophys Res Commun. 2019;516(1):183–188. doi:10.1016/j.bbrc.2019.05.189.
   PubMed Web of Science ®Google Scholar
• Wang X, et al. Metabolomics analysis of multidrug resistance in colorectal cancer cell and multidrug resistance reversal effect of verapamil. Biomed Chromatogr. 2021;35(2):e4976.
   PubMed Web of Science ®Google Scholar
• Shiozaki A, Katsurahara K, Otsuji E. ASO author reflections: amlodipine and verapamil, voltage-gated Ca(2+) channel inhibitors suppressed the growth of gastric cancer stem cells. Ann Surg Oncol. 2021;28(9):5412–5413. doi:10.1245/s10434-021-09647-y.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qin S, Chen Y, et al. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. 2022;14(2):e14903. doi:10.15252/emmm.202114903.
   PubMed Web of Science ®Google Scholar
• Crabtree GR, Schreiber SL. SnapShot: ca2+-calcineurin-NFAT signaling. Cell. 2009;138(1):210, 210.e1–210.e1. doi:10.1016/j.cell.2009.06.026.
   PubMed Web of Science ®Google Scholar
• Ding W, Dong M, Deng J, et al. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway. Am J Physiol Heart Circ Physiol. 2014;307(5):H792–802. doi:10.1152/ajpheart.00017.2014.
   PubMed Web of Science ®Google Scholar
• Müller MR, Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol. 2010;10(9):645–656. doi:10.1038/nri2818.
   PubMed Web of Science ®Google Scholar
• Heim L, Friedrich J, Engelhardt M, et al. NFATc1 promotes antitumoral effector functions and memory CD8(+) T-cell differentiation during Non-Small cell lung cancer development. Cancer Res. 2018;78(13):3619–3633. doi:10.1158/0008-5472.CAN-17-3297.
   PubMed Web of Science ®Google Scholar
• Quang CT, et al. The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells. Cell Death Dis. 2015;6(2):e1658.
   PubMedGoogle Scholar
• Müller DJ, Wirths S, Fuchs AR, et al. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. J Leukoc Biol. 2019;105(3):531–538. doi:10.1002/JLB.2AB0218-076RR.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Liu L, et al. NFAT2 overexpression suppresses the malignancy of hepatocellular carcinoma through inducing Egr2 expression. BMC Cancer. 2020;20(1):966. doi:10.1186/s12885-020-07474-0.
   PubMed Web of Science ®Google Scholar